# Round 2 — Editor Reviewer (JCO CCI)

**Round**: 02
**Reviewer**: Target-journal Editor (per `prompts/03-reviewer-editor.md`)
**Date**: 2026-05-21
**Target journal**: JCO Clinical Cancer Informatics
**Reviewed artefacts**: `case-study/manuscript/main.tex` at HEAD post-
commit `d7b9918`, `case-study/manuscript/JOURNAL.md`,
`case-study/manuscript/cover-letter.md`,
`case-study/manuscript/references.bib`, `docs/ai-usage-disclosure.md`.

## Overall impression

The novelty statement that Round 1 demanded is now embedded in the
Introduction — the auditable optimism-correction + intersect-rebuild
contract is positioned as the informatics contribution. The AI-
disclosure compliance language is updated. Reference style is
correctly rendered as superscript-numeric in the compiled PDF.
Cover-letter and manuscript framing are now aligned on the
"illustrative, not for clinical use" caveat.

Body word count: 2,581 words (`texcount`), comfortably under the 3,000
JCO CCI cap.

The remaining items are minor polish.

## Per-Round-1-comment status

| R1 ID | Status | Notes |
|-------|--------|-------|
| 1 (novelty positioning) | resolved | Introduction has a dedicated novelty paragraph; positioning is "an auditable, agent-produced prognostic-model pipeline whose preregistration trail and failure-mode log are the informatics contribution, not the 50-gene panel". This is a defensible novelty statement for JCO CCI. |
| 2 (word count tracking) | resolved | 2,581 words, under cap. |
| 3 (PubMed verification of refs) | resolved | Villanueva 2015->2019 corrected; all 22 references resolvable. |
| 4 (author-review statement) | resolved | AI Usage Statement includes "The author reviewed and validated all AI-generated text, code, and interpretations before submission." |
| 5 (tag placeholder) | deferred | To be replaced with `case-study-v1.0.0` at tagging time. |
| 6 (rendered superscript citations) | resolved | Verified on PDF; `[1, 2]`-style superscript present. |
| 7 (cover-letter framing) | resolved | Cover letter aligned to "illustrative" framing. |
| 8 (figure budget) | resolved | 5 figures, at the JCO CCI limit. |
| 9 (plain-language summary) | resolved | Present. |
| 10 (title shortening) | resolved | New title is 17 words: "An Optimism-Corrected Transcriptomic Risk Score Refines Overall-Survival Stratification Beyond AJCC Pathologic Stage in Hepatocellular Carcinoma". |

## New Round-2 comments

### Comment 1 [LOW] — Cover letter contribution paragraph

The cover letter (`case-study/manuscript/cover-letter.md`) presents
the contribution well. One refinement: the opening paragraph should
also cite the reproducibility-tag commitment explicitly: "The
manuscript ships with a tagged GitHub release (`case-study-v1.0.0`)
that contains every analysis script, every reviewer-round transcript,
and every failure-mode document referenced in the text. A
reproducibility-check script (`case-study/analysis/99_reexec_check.py`)
asserts that the committed numerical artefacts match the pipeline's
re-execution within prespecified tolerances."

Severity: low.

### Comment 2 [LOW] — TRIPOD checklist as supplementary

The manuscript states TRIPOD adherence. The submission package should
include a filled-out TRIPOD checklist as supplementary material (PDF
or DOCX). Track this for submission.

Severity: low. Planning item.

### Comment 3 [LOW] — Reference 22 in references.bib (Forner 2018 Lancet)

The reference is correct (PMID 29307467). Just noting that JCO CCI's
AMA-style citations would typically render this as authors' surnames
+ initials; verify on the compiled PDF that the formatting is correct.

Severity: low.

## Verdict

**`accept`**.

The Round-1 editorial blocker (novelty positioning) is resolved.
Format compliance, scope fit, AI-disclosure compliance, and
reproducibility are all in order. The cover letter is appropriately
framed. Reference list is verified.

Tagged-release identifier replacement (Comment R1-#5) is deferred to
the case-study-v1.0.0 commit boundary, which is the conventional
practice for prepublication archiving.
